Search for Clinical Trial Results

Sponsored By

Corneal Neovascularization - 20 Studies Found

Status Study
Completed Study Name: Bevacizumab for the Treatment of Corneal Neovascularization
Condition: Corneal Neovascularization
Date: 2009-10-08
Interventions: Drug: Bevacizumab Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
Completed Study Name: Treatment of Corneal Neovascularization With Topical Pazopanib
Condition: Corneal Neovascularization
Date: 2010-11-22
Interventions: Drug: Pazopanib (5mg/ml) Topical pazopanib, 4 times per day for 3 weeks
Completed Study Name: Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
Condition: Corneal Neovascularization
Date: 2007-11-07
Interventions: Drug: Bevacizumab (Avastin) One dose of 0.1cc of subconjunctival Bevacizumab was applied
Completed Study Name: The Effect of Bevacizumab on Corneal Neovascularization
Condition: Corneal Neovascularization
Date: 2008-11-22
Interventions: Drug: Bevacizumab subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 mon
Not yet recruiting Study Name: Strategies for Management of Corneal Neovascularisation
Condition: Corneal Neovascularisation
Date: 2015-10-27
Interventions:
  • Device: Fine Needle Diathermy

Terminated Study Name: Topical IL-1-Ra for Treatment of Corneal Neovascularization
Condition: Corneal Neovascularization
Date: 2009-06-04
Interventions:
  • Drug: Placebo Custom eye drop

Completed Study Name: Topical Avastin for Treatment of Corneal Neovascularization
Condition: Corneal Neovascularization
Date: 2007-11-14
Interventions: Drug: Topical Avastin 1% Avastin (bevacizumab) 1% Ot
Completed Study Name: Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
Condition: Corneal Neovascularization
Date: 2008-05-19
Interventions: Drug: Ranibizumab 10 Patients will receive treatment (Ranibizumab)
Completed Study Name: Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Condition: Corneal Neovascularization
Date: 2007-08-06
Interventions: Drug: Bevacizumab (Avastin) Bevacizumab 10mg/mL 1 drop BID x 3 weeks
Completed Study Name: Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
Condition: Corneal Neovascularization
Date: 1999-10-18
Interventions:
  • Drug: Dihematoporphyrin derivative
  • Drug: p
Next >>>